Genmab AS
Sector and Industry
Healthcare, Biopharmaceuticals
Performance (1Y)
9.57%
Market Cap
12.15 Bil.
P/E Ratio
19.78
Dividend Yield
0.00 %
Earnings per Share
13.76 €
Peer Group
| Company Name | Market Cap | Revenue Last Reported Year | P/E Ratio | Profit Growth 1Y | Last Price | Previous Trading Day Change |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | 864.54 Bil. | 57.78 Bil. | 46.82 | +86.88 % | 0.00 | - |
| Johnson & Johnson | 425.70 Bil. | 83.48 Bil. | 18.82 | +82.71 % | 0.00 | - |
| AbbVie Inc. | 343.94 Bil. | 54.21 Bil. | 96.78 | -5.29 % | 0.00 | - |
| Roche Holding AG | 286.62 Bil. | 65.80 Bil. | 20.72 | +58.45 % | 0.00 | - |
| AstraZeneca PLC | 244.91 Bil. | 52.09 Bil. | 27.55 | +39.41 % | 0.00 | - |
| NOVARTIS AG | 224.76 Bil. | 48.44 Bil. | 18.30 | +12.45 % | 0.00 | - |
| Merck & Co. Inc. | 221.79 Bil. | 57.55 Bil. | 14.46 | +2.25 % | 0.00 | - |
| Novo-Nordisk AS B | 193.52 Bil. | 41.49 Bil. | 14.11 | +1.54 % | 0.00 | - |
| Amgen Inc. | 150.16 Bil. | 32.57 Bil. | 23.01 | +80.77 % | 0.00 | - |
| Gilead Sciences Inc. | 129.70 Bil. | 26.10 Bil. | 18.10 | +1,599.93 % | 0.00 | - |
Facts & figures
Price data
| TRADE PLATFORM | Börse Stuttgart (XSTU) | |
| LAST PRICE | 204.2 G | 0 Units |
| PRICE DETERMINATION TIME | 06/03/2026 / 09:56:53 PM | |
| DAILY VOLUME (UNITS) | 6 | |
| DAILY HIGH / LOW | 205 | 202.8 |
| PREV. DAY'S PRICE | 204.4 | (06/02) |
| CHANGE DAY BEFORE | -0.20 | -0.10 % |
| 52 WEEK HIGH / LOW | 304.5 (01/15) | 171.1 (07/04) |
Key Figures (in EUR)
| 2027e | 2026e | 2025 | 2024 | 2023 | |
|---|---|---|---|---|---|
| EARNINGS PER SHARE | 14.91 | 9.70 | 13.76 | 16.39 | 8.95 |
| DIVIDENDS PER SHARE | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| DIVIDEND YIELD IN % | - | - | 0.00 % | 0.00 % | 0.00 % |
| DIVIDEND GROWTH IN % | - | - | - | - | - |
| PRICE - EARNINGS RATIO | 15.29 | 23.51 | 19.78 | 12.21 | 32.34 |
| PRICE - BOOK RATIO | - | - | 3.36 | 2.58 | 4.45 |
| PRICE - SALES RATIO | - | - | 5.17 | 4.48 | 8.62 |
| PRICE - CASH FLOW RATIO | - | - | 16.20 | 12.41 | 19.25 |
Master Data
| WKN | 565131 |
| ISIN | DK0010272202 |
| SYMBOL | GE9 |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Equity |
| DENOMINATION | GENMAB |
| INDEX MEMBERSHIP | - |
| TRADING SEGMENT | - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| TRADING CURRENCY | Euro |
| NOMINAL CURRENCY | Danish Krone |
| SETTLEMENT CURRENCY | Euro |
| SECTOR AND INDUSTRY | Healthcare, Biopharmaceuticals |
| NUMBER OF SHARES | 59.49 Mil. |
| MARKET CAPITALISATION | 12.15 Bil. |
Performance overview
| 1W | 1M | 3M | 6M | 1Y | 3Y | 5Y | YTD | |
|---|---|---|---|---|---|---|---|---|
| PERFORMANCE | -10.94 % | -9.24 % | -18.95 % | -24.88 % | 9.57 % | -43.16 % | -38.23 % | -24.04 % |
| HIGH | 233.30 | 239.90 | 250.60 | 304.50 | 304.50 | 380.40 | 447.00 | 304.50 |
| LOW | 204.40 | 204.40 | 204.40 | 204.40 | 171.10 | 160.50 | 160.50 | 204.40 |
Dividend
per share
GENMAB does not deliver dividend information
Company profile
Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma, teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease, and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark.
Structured products for Genmab AS
Analyst Rating
Ø-Target Price DistanceNot Available
Current Price
Not AvailableØ-Target Price
Not AvailableAverage ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0
Company Events
No company events available.